Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence

Antonio Martín Morales1, Vincenzo Mirone2, John Dean3, Pierre Costa41Department of Urology, Hospital Carlos Haya, Malaga, Spain; 2Department of Urology, University Federico II, Naples, Italy; 3St. Peter’s Sexual Medicine, The London Clinic, London, UK; 4Center Hospitalier Careme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Martín Morales, Vincenzo Mirone, John Dean, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	vardenafil erectile dysfunction efficacy safety underlying conditions Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/20128d81409b4197bc8a8f41d49deb92
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20128d81409b4197bc8a8f41d49deb92
record_format	dspace
spelling	oai:doaj.org-article:20128d81409b4197bc8a8f41d49deb922021-12-02T09:17:53ZVardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence1178-1998https://doaj.org/article/20128d81409b4197bc8a8f41d49deb922009-12-01T00:00:00Zhttps://www.dovepress.com/vardenafil-for-the-treatment-of-erectile-dysfunction-an-overview-of-th-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Antonio Martín Morales1, Vincenzo Mirone2, John Dean3, Pierre Costa41Department of Urology, Hospital Carlos Haya, Malaga, Spain; 2Department of Urology, University Federico II, Naples, Italy; 3St. Peter’s Sexual Medicine, The London Clinic, London, UK; 4Center Hospitalier Caremeau, Nîmes, FranceAbstract: Many men with erectile dysfunction (ED) also have associated underlying cardiovascular and metabolic conditions, for which they are likely to be taking medication. Therefore, cardiovascular safety and potential drug interactions are two of the major concerns when using PDE-5 inhibitors in these patients. The PDE-5 inhibitor, vardenafil, is characterized by a rapid onset of action, increased duration of erection, high rates of first-dose success and reliable efficacy that can be maintained with continued use. In both clinical trials and real-life observational studies, vardenafil has demonstrated a favorable efficacy and safety profile in men with ED, including those with associated underlying conditions such as diabetes, hypertension and dyslipidemia. Importantly, the concomitant use of medication for these conditions is not associated with any noteworthy changes in the efficacy and safety of vardenafil. The evidence presented in this review supports the use of vardenafil as a first-line treatment for men with ED, including those with underlying conditions.Keywords: vardenafil, erectile dysfunction, efficacy, safety, underlying conditionsAntonio Martín MoralesVincenzo MironeJohn Deanet alDove Medical Pressarticlevardenafilerectile dysfunctionefficacysafetyunderlying conditionsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 463-472 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	vardenafil erectile dysfunction efficacy safety underlying conditions Geriatrics RC952-954.6
spellingShingle	vardenafil erectile dysfunction efficacy safety underlying conditions Geriatrics RC952-954.6 Antonio Martín Morales Vincenzo Mirone John Dean et al Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
description	Antonio Martín Morales1, Vincenzo Mirone2, John Dean3, Pierre Costa41Department of Urology, Hospital Carlos Haya, Malaga, Spain; 2Department of Urology, University Federico II, Naples, Italy; 3St. Peter’s Sexual Medicine, The London Clinic, London, UK; 4Center Hospitalier Caremeau, Nîmes, FranceAbstract: Many men with erectile dysfunction (ED) also have associated underlying cardiovascular and metabolic conditions, for which they are likely to be taking medication. Therefore, cardiovascular safety and potential drug interactions are two of the major concerns when using PDE-5 inhibitors in these patients. The PDE-5 inhibitor, vardenafil, is characterized by a rapid onset of action, increased duration of erection, high rates of first-dose success and reliable efficacy that can be maintained with continued use. In both clinical trials and real-life observational studies, vardenafil has demonstrated a favorable efficacy and safety profile in men with ED, including those with associated underlying conditions such as diabetes, hypertension and dyslipidemia. Importantly, the concomitant use of medication for these conditions is not associated with any noteworthy changes in the efficacy and safety of vardenafil. The evidence presented in this review supports the use of vardenafil as a first-line treatment for men with ED, including those with underlying conditions.Keywords: vardenafil, erectile dysfunction, efficacy, safety, underlying conditions
format	article
author	Antonio Martín Morales Vincenzo Mirone John Dean et al
author_facet	Antonio Martín Morales Vincenzo Mirone John Dean et al
author_sort	Antonio Martín Morales
title	Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
title_short	Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
title_full	Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
title_fullStr	Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
title_full_unstemmed	Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
title_sort	vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/20128d81409b4197bc8a8f41d49deb92
work_keys_str_mv	AT antoniomartiacutenmorales vardenafilforthetreatmentoferectiledysfunctionanoverviewoftheclinicalevidence AT vincenzomirone vardenafilforthetreatmentoferectiledysfunctionanoverviewoftheclinicalevidence AT johndean vardenafilforthetreatmentoferectiledysfunctionanoverviewoftheclinicalevidence AT etal vardenafilforthetreatmentoferectiledysfunctionanoverviewoftheclinicalevidence
_version_	1718398172035809280

Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence

Ejemplares similares